{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Philadelphia-Positive+Myeloid+Leukemia&page=26", "query": { "condition": "Philadelphia-Positive Myeloid Leukemia", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 931, "total_pages": 94, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Philadelphia-Positive+Myeloid+Leukemia&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Philadelphia-Positive+Myeloid+Leukemia&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T07:37:24.110Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01424982", "title": "Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Lymphoblastic Leukemia", "Adult Acute Lymphoblastic Leukemia in Complete Remission", "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Philadelphia Chromosome Positive", "Untreated Adult Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Ponatinib", "type": "DRUG" }, { "name": "Ponatinib Hydrochloride", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2011-10-05", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-14T07:37:24.110Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01424982" }, { "nct_id": "NCT00003913", "title": "Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 390, "start_date": "1998-12", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2010-04-02", "last_synced_at": "2026-10-14T07:37:24.110Z", "location_count": 23, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 18 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003913" }, { "nct_id": "NCT00608517", "title": "Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "50 Years", "sex": "ALL", "summary": "Up to 50 Years" }, "enrollment_count": 6, "start_date": "2005-09", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2014-05-20", "last_synced_at": "2026-10-14T07:37:24.110Z", "location_count": 4, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00608517" }, { "nct_id": "NCT00988013", "title": "Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Myeloid Leukemia", "Lymphoblastic Leukemia", "Acute Leukemia", "Non Hodgkins Lymphoma", "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "IM-TMI (3Gy)", "type": "RADIATION" }, { "name": "IM-TMI (6Gy)", "type": "RADIATION" }, { "name": "IM-TMI (9Gy)", "type": "RADIATION" }, { "name": "IM-TMI (12Gy)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 14, "start_date": "2009-09", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2021-06-14", "last_synced_at": "2026-10-14T07:37:24.110Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00988013" }, { "nct_id": "NCT00381550", "title": "3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Essential Thrombocythemia", "Philadelphia Chromosome Negative Chronic Myelogenous Leukemia", "Polycythemia Vera", "Primary Myelofibrosis", "Relapsing Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "triapine", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2006-08", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2015-01-06", "last_synced_at": "2026-10-14T07:37:24.110Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00381550" }, { "nct_id": "NCT00131989", "title": "Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2005-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-09", "last_synced_at": "2026-10-14T07:37:24.110Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00131989" }, { "nct_id": "NCT00053989", "title": "NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases", "Fanconi Anemia", "Aplastic Anemia" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "graft-versus-tumor induction therapy", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "4 Years to 75 Years" }, "enrollment_count": 41, "start_date": "2002-01-29", "completion_date": "2018-07-19", "has_results": true, "last_update_posted_date": "2020-02-10", "last_synced_at": "2026-10-14T07:37:24.110Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053989" }, { "nct_id": "NCT00623870", "title": "A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "RO5045337", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2008-05", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-14T07:37:24.110Z", "location_count": 4, "location_summary": "Duarte, California • New Brunswick, New Jersey • New York, New York + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00623870" }, { "nct_id": "NCT00005797", "title": "Bone Marrow Transplant in Treating Patients With Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Multiple Myeloma and Malignant Plasma Cell Neoplasms", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "VP-16", "type": "DRUG" }, { "name": "Fractionated Total Body Irradiation (FTBI)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "15 Years to 55 Years" }, "enrollment_count": 125, "start_date": "1993-03", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2020-12-10", "last_synced_at": "2026-10-14T07:37:24.110Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005797" }, { "nct_id": "NCT01392170", "title": "Pegasys in Patients With Chronic Myeloid Leukemia (CML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "PEG-IFNá-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 2, "start_date": "2011-10", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2015-05-04", "last_synced_at": "2026-10-14T07:37:24.110Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01392170" } ] }